SBIR Phase II: Magnetic Capture Device for Rapid Isolation of Rare Cells

SBIR II 期：用于快速分离稀有细胞的磁捕获装置

• 批准号: 1430998
• 负责人: Matthew Kerby
• 金额: $ 75万
• 依托单位: CytoMag, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-10-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1430998&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Magnetic; Capture

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to develop a technology to enable personalized healthcare for patients. This project will create a separation device to recover rare cells, including circulating tumor cells (CTC) from cancer, which can be analyzed for genetic mutations. In the long term, this information could direct cancer therapy for each patient. Currently available CTC tests only count rare cancer cells, which is of limited value to doctors. This SBIR project will produce an automated system to capture cancer cells from blood, and recover live cells for analysis. Through a small sample of blood, a cancer patient's tumor may be genotyped, which may enable custom therapy in the future. The platform has many research and clinical uses for any type of rare cell capture and analysis. The proposed automated cell separation device will enable the translation of basic research to clinical application by simplifying the rare cell isolation process. This SBIR Phase II project proposes to develop an improved device for the detection and analysis of circulating tumor cells (CTCs) shed into the blood from cancer sites. CTCs are part of the process of spreading cancer, and early detection is key to improved treatment. Detection, quantification, and characterization of CTCs has the potential to transform oncology, yet isolation under routine conditions of these rare, one-in-a-billion cells, remains problematic. The proposed CTC sample preparation technology under development is low-cost, rapid, and potentially may provide a highly informative analysis of captured cells. It promises to enable a new generation of cancer diagnostics that impact patient care. During this Phase II project, the goal is to design and produce the separation device, a fluidic workstation, and supply kit; then, evaluate its ability to capture and recover CTCs from the blood of cancer patients. The Phase I data demonstrate the feasibility of this approach. The results of this study will evaluate alternative means of capturing and recovering CTCs, with the goal of 90% recovery of cells in a procedure requiring 60 minutes or less. A secondary goal of Phase II is to evaluate the potential of the device for the isolation of fetal cells from maternal blood, which could enable noninvasive prenatal diagnostics.

小型企业创新研究(SBIR)第二阶段项目的更广泛影响/商业潜力是开发一种为患者提供个性化医疗保健的技术。该项目将创建一种分离设备，以回收稀有细胞，包括从癌症中提取的循环肿瘤细胞(CTC)，这些细胞可以分析基因突变。从长远来看，这些信息可以指导每个患者的癌症治疗。目前可用的CTC检测只计算罕见的癌细胞，这对医生的价值有限。这个SBIR项目将生产一种自动化系统，从血液中捕获癌细胞，并回收活细胞进行分析。通过一小块血液样本，癌症患者的肿瘤可能会被基因分型，这可能会在未来实现定制治疗。该平台对任何类型的稀有细胞捕获和分析都有许多研究和临床应用。拟议的自动细胞分离设备将通过简化稀有细胞分离过程，使基础研究转化为临床应用。这个SBIR第二阶段项目建议开发一种改进的设备，用于检测和分析从癌症部位流入血液的循环肿瘤细胞(CTCs)。CTC是癌症传播过程的一部分，早期发现是改进治疗的关键。CTCs的检测、量化和表征有可能改变肿瘤学，但在常规条件下分离这些罕见的十亿分之一的细胞仍然存在问题。拟议的CTC样品制备技术正在开发中，该技术成本低、速度快，可能提供对捕获细胞的高度信息量分析。它有望实现影响患者护理的新一代癌症诊断。在这个二期项目中，目标是设计和生产分离设备、一个流体工作站和供应试剂盒；然后评估其从癌症患者血液中捕获和回收CTCs的能力。第一阶段的数据证明了该方法的可行性。这项研究的结果将评估捕获和回收CTCs的替代方法，目标是在需要60分钟或更短的过程中恢复90%的细胞。第二阶段的第二个目标是评估该设备从母体血液中分离胎儿细胞的潜力，这可能使非侵入性产前诊断成为可能。